title: Expression and distribution of mTOR, p70S6K, 4E-BP1, and their phosphorylated counterparts in rat dorsal root ganglion and spinal cord dorsal horn.
abstract: Mammalian target of rapamycin (mTOR) controls protein translation and has an important role in the mechanism of pain hypersensitivity under persistent pain conditions. However, its expression and localization in pain-related regions of the nervous system is not completely understood. Here, we examined the expression and distribution of mTOR, eukaryotic initiation factor 4E-binding protein1/2 (4E-BP1/2), p70 ribosomal S6 protein kinase (p70S6K), and their phosphorylated (active) counterparts in two major pain-related regions, the dorsal root ganglion (DRG) and spinal cord dorsal horn. Reverse transcriptase-polymerase chain reaction showed that mTOR, 4E-BP1, and p70S6K mRNA are expressed in the DRG and dorsal horn. Western blot analysis further confirmed the existence of their protein products in these two regions, but expression of their phosphorylated counterparts was very low in dorsal horn and was not detected in the DRG. Immunohistochemistry revealed mTOR and p70S6K in the DRG neurons. Quantitative analysis showed that approximately 26.1% (+/- 3.2%) of DRG neurons were positive for mTOR and 19.1% (+/- 1.9%) were positive for p70S6K. Most of these neurons were small-less than 600 microm(2) in cross-sectional area-and some co-labeled with substance P or isolectin B4. Surprisingly, 4E-BP1 was observed only in the DRG satellite glial cells. In the dorsal horn, mTOR, p70S6K, and 4E-BP1 were detected in neurons, but not in astrocytes or microglia. They were distributed in the whole dorsal horn, especially in the superficial dorsal horn. Immunostaining for their phosphorylated counterparts was very low or undetectable in DRG and dorsal horn. Behavioral study showed that intrathecal mTOR inhibitor, rapamycin, did not affect acute nocicepetive transmission. The results indicate that although mTOR, p70S6K, and 4E-BP1 are highly expressed in the DRG and dorsal horn, their activate forms are very low in both regions under normal conditions. Our findings support the view that mTOR and its downstream effectors do not play a key role in acute pain.
authors.affiliation: Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
authors.forename: Ji-Tain
authors.initials: JT
authors.lastname: Xu
authors.forename: Xiuli
authors.initials: X
authors.lastname: Zhao
authors.forename: Myron
authors.initials: M
authors.lastname: Yaster
authors.forename: Yuan-Xiang
authors.initials: YX
authors.lastname: Tao
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002352:Carrier Proteins / Q000096:biosynthesis* / Q000235:genetics; D005727:Ganglia, Spinal / Q000378:metabolism*; D015870:Gene Expression; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics; D010146:Pain / Q000378:metabolism*; D010750:Phosphoproteins / Q000096:biosynthesis* / Q000235:genetics; D010766:Phosphorylation; D020671:Posterior Horn Cells / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000096:biosynthesis* / Q000235:genetics; D058570:TOR Serine-Threonine Kinases
chemical_list: D002352:Carrier Proteins; C499526:Eif4ebp1 protein, rat; D047908:Intracellular Signaling Peptides and Proteins; D010750:Phosphoproteins; D012333:RNA, Messenger; C546845:mTOR protein, rat; D017346:Protein Serine-Threonine Kinases; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases
references.citation: Neuroscience. 2009 Jun 2;160(4):847-57
references.pmid: 19303429
references.citation: PLoS One. 2008 Apr 09;3(4):e1961
references.pmid: 18398477
references.citation: J Neurosci. 2009 Nov 25;29(47):15017-27
references.pmid: 19940197
references.citation: Biochim Biophys Acta. 2008 Jan;1784(1):116-32
references.pmid: 17913600
references.citation: Neuroscience. 2004;123(4):1045-51
references.pmid: 14751295
references.citation: Biochem J. 2007 Apr 15;403(2):217-34
references.pmid: 17376031
references.citation: Proteomics. 2009 Mar;9(5):1241-53
references.pmid: 19206110
references.citation: J Neurosci. 2007 Dec 19;27(51):13958-67
references.pmid: 18094233
references.citation: Mol Pain. 2009 Jun 07;5:27
references.pmid: 19500426
references.citation: J Neurosci. 2004 Nov 3;24(44):9760-9
references.pmid: 15525761
references.citation: Mol Pain. 2008 Oct 14;4:45
references.pmid: 18851757
references.citation: FEBS J. 2005 Aug;272(16):4211-20
references.pmid: 16098202
references.citation: Eur J Pain. 2010 Jan;14(1):49.e1-11
references.pmid: 19345595
references.citation: Mol Pain. 2008 Dec 30;4:67
references.pmid: 19116032
references.citation: J Pain. 2009 Sep;10(9):895-926
references.pmid: 19712899
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2009 Nov;380(5):459-63
references.pmid: 19756519
references.citation: Eur J Neurosci. 2009 Jun;29(12):2253-63
references.pmid: 19490023
references.citation: J Neurosci. 2009 Mar 11;29(10):3206-19
references.pmid: 19279258
references.citation: Genes Dev. 2004 Aug 15;18(16):1926-45
references.pmid: 15314020
references.citation: J Neurosci. 2004 Nov 10;24(45):10211-22
references.pmid: 15537893
references.citation: Mol Neurobiol. 2006 Dec;34(3):205-19
references.pmid: 17308353
references.citation: Brain Behav Immun. 2007 Jul;21(5):592-8
references.pmid: 17222529
references.citation: Cancer Res. 2007 Aug 15;67(16):7551-5
references.pmid: 17699757